{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.139","value":"-0.32"},{"groupId":"OG001","spread":"0.285","value":"0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"BPI-SF Pain Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.147","value":"-0.28"},{"groupId":"OG001","spread":"0.302","value":"0.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"BPI-SF Interference Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Changes in health and pain status from baseline to week 25 using: Brief Pain Inventory-Short Form (BPI-SF) questionnaire (on a scale of 1 to 10, from mild to severe, for pain and pain-interference scores). A decrease indicates less severe pain/interference. Assessments completed during screening, at study treatment visits (Day 1, Day 15, Day 29, Day 43, Day 57, and every 29 days thereafter) (during the Treatment Phase, the Treatment Discontinuation Visit, and during the Follow-up Phase.","dispersionType":"Standard Error","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"MEAN","populationDescription":"ITT Population with BRCA mutated mCRPC. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable for specified category.","reportingStatus":"POSTED","timeFrame":"From enrollment to up to approximately 25 weeks","title":"Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: BPI-SF","type":"SECONDARY","unitOfMeasure":"units on a scale"}